Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEMZAR · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| GEMZAR | DRUG | - |
| ALIMTA | DRUG | - |
Inclusion Criteria: * Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body. * You must have one tumor that can be physically measured or scanned by the doctor. * You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pa...
GEMZAR is an investigational small molecule being studied for the treatment of pancreatic neoplasms, including unresectable or metastatic cancer of the pancreas. It is in Phase 3 clinical development for this oncology indication.
GEMZAR is being developed by Eli Lilly and Company, which trades under the ticker LLY. The drug is currently in Phase 3 clinical trials for pancreatic neoplasms.
GEMZAR is in Phase 3 clinical development. It is an investigational drug being studied for pancreatic neoplasms and has not been approved for this indication.
GEMZAR is being studied in a Phase 3 clinical trial with the identifier NCT00035035. This completed trial evaluated ALIMTA (pemetrexed) plus GEMZAR versus GEMZAR alone in patients with unresectable or metastatic cancer of the pancreas.
No, GEMZAR is not the same as ALIMTA. In the Phase 3 clinical trial NCT00035035, ALIMTA (pemetrexed) was given in combination with GEMZAR, and the combination was compared against GEMZAR alone in patients with pancreatic cancer.